Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study

Lung, Respiratory and Thoracic Cancer

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Zhu H, Al Saifi S, Bahig H, Cooper A, Abrão FC, Corrales L, Faivre-Finn C, Filippi AR, Fitzgerald B, Khosla D, Lam VK, Le X, Menezes V, Newsom-Davis T, Qin A, Putora PM, Munoz-Schuffenegger P, Siva S, Yu NY, Louie AV

doi: 10.1016/j.jtho.2025.11.006

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A

doi: 10.1016/j.lungcan.2026.109336

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A

doi: 10.1016/j.cllc.2025.06.005

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Lung, Respiratory and Thoracic Cancer

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Lung Cancer

Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S

doi: 10.1016/j.lungcan.2025.108496

Lung, Respiratory and Thoracic Cancer

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Lung Cancer

Zhang Q, Yang Y, Xie M, Zhou Z, Wu H, Zhai W, Chen Y, Chen K, Zhou S, Li H, Fan Y

doi: 10.1016/j.lungcan.2025.108616

Lung, Respiratory and Thoracic Cancer

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Lung Cancer

Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators

doi: 10.1016/j.lungcan.2025.108802

Lung, Respiratory and Thoracic Cancer

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

Lung Cancer

Dingemans AC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Felip E, Griesinger F, Ohashi K, Zalcman G, Hughes BGM, Sørensen JB, Blais N, Ferreira CGM, Lindsay CR, Dziadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S

doi: 10.1016/j.lungcan.2025.108683

Related content

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial